HERON THERAPEUTICS INC (HRTX:NASDAQ)
$0.3321 0.0199 (6.3741%)
Analysed HERON THERAPEUTICS INC (HRTX:NASDAQ) News Sources
Acute Care Revenue Growth Helps Heron (HRTX) Reaffirm 2026 Guidance Despite Q1 Sales Decline
11-05-2026
advfn.com
Heron Therapeutics Q1 Earnings Call Highlights
11-05-2026
marketbeat.com
Heron Therapeutics Inc (HRTX) Q1 2026 Earnings Call Highlights: Resilient Growth Amidst Challenges
12-05-2026
yahoo.com
U.S. District Court Issues Decision Regarding CINVANTI® Patents
02-06-2026
yahoo.com
Heron Therapeutics (HRTX) Stock Sees Fair Value Cut After Cinvanti Patent Decision
12-07-2026
yahoo.com
Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026
27-07-2026
yahoo.com
Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates
10-08-2026
yahoo.com
Heron Therapeutics Q2 Earnings Call Highlights
10-08-2026
marketbeat.com
Heron Therapeutics Withdraws 2026 Guidance as CINVANTI Patent Risk and Strategic Review Cloud Outlook
10-08-2026
advfn.com
Heron Therapeutics Inc (HRTX) (Q2 2026) Earnings Call Highlights: Revenue Growth Amid Strategic ...
10-08-2026
yahoo.com
What is the current price of HERON THERAPEUTICS INC (HRTX:NASDAQ)?
The current price of HERON THERAPEUTICS INC (HRTX:NASDAQ) is $0.3321.
HERON THERAPEUTICS INC (HRTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of HERON THERAPEUTICS INC (HRTX:NASDAQ) since the previous trading day is $0.0199.
HERON THERAPEUTICS INC (HRTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of HERON THERAPEUTICS INC (HRTX:NASDAQ) since the previous trading day is 6.3741%.
What is the most recent average sentiment score for HERON THERAPEUTICS INC (HRTX:NASDAQ)?
The most recent average sentiment score for HERON THERAPEUTICS INC (HRTX:NASDAQ) is 61 out of 100.
What is the most recent average sentiment for HERON THERAPEUTICS INC (HRTX:NASDAQ)?
The most recent sentiment for HERON THERAPEUTICS INC (HRTX:NASDAQ) is .
SEC-8K** Filing Available For HERON THERAPEUTICS INC (HRTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.